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and Central of review and dissemination (CRD databases) from 1966–June 2009. 
Keywords included macular degeneration with preference or utility or names of all 
possible techniques/tools used to derive utility or other synonyms. Original articles 
reporting health state utilities of patients with AMD were included. All articles were 
reviewed and extracted independently by two investigators for study design, popula-
tion and outcomes. Meta-analyses were performed using DerSimonian and Laird 
method under a random-effects model. RESULTS: Out of 1887 studies identiﬁ ed, 24 
studies met inclusion criteria. Twenty-one studies obtained utility directly from 
patients, while the others inquired ophthalmologists or community members to esti-
mate utility. Standard Gamble (SG) and time-trade off (TTO) were the most commonly 
techniques used in these studies (11 studies used TTO, while 5 studies used SG). Based 
on a meta-analysis of three studies which obtained utility from 510 patients and 
provided sufﬁ cient data for calculation, the utility values with 95% conﬁ dence inter-
vals for visual acuity of 20/20–20/25, 20/30–20/50, 20/60–20/100, 20/200–20/400 
and <20/400 were 0.91 (0.88–0.94), 0.81 (0.78–0.84), 0.68 (0.58–0.77), 0.62 (0.55–
0.68), and 0.46 (0.33–0.59) respectively. CONCLUSIONS: Our ﬁ ndings provided the 
pooled estimates of utilities for AMD patients for all visual acuity levels. It was found 
that the better visual acuity, the higher utility value. Researchers may use our pooled 
utilities as input parameters in their cost-effectiveness modeling studies. 
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OBJECTIVES: Psoriasis has a major impact on patients’ quality of life, as commonly 
measured by the Dermatology Life Quality Index (DLQI). This study has two objec-
tives: 1) to measure health-related utilities for patients with psoriasis and to measure 
the willingness-to-pay (WTP) for a cure for psoriasis, and 2) to examine how these 
different measures of utilities and WTP were related to DLQI. METHODS: Face-to-
face patient interviews were carried out with 364 patients with psoriasis during August 
2009 and February 2010 at dermatology outpatient clinics in ﬁ ve hospitals located in 
northern, central and southern Taiwan. Utilities were elicited using time trade-off 
(TTO), visual analogue scale (VAS) and EQ-5D. The EQ-5D was scored based on the 
standard scoring formula. The WTP for a cure of psoriasis was elicited by double 
bounded binary-choice questions followed by a bidding game question. RESULTS: 
Mean age was 44.5 years, mean history of disease was 11.2 years, and 77% of patients 
were male. The mean health utility was 0.87 (EQ-5D), 0.72 (VAS) and 0.75 (TTO). 
The WTP per month was between NT$7770.72 and NT$9411.50. Scores of EQ-5D 
and VAS were signiﬁ cantly negatively correlated to all of the dimensions of DLQI. 
The correlation of the dichotomous WTP with DLQI was also strong and in the 
expected direction. TTO was also signiﬁ cantly correlated with DLQI, but the relation 
was the weakest. CONCLUSIONS: EQ-5D, VAS and WTP are consistent measures 
with DLQI in assessing the well-being of patients with psoriasis in Taiwan. 
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OBJECTIVES: The impact of choice of pharmacotherapy for psoriasis on costs and 
patient outcomes in large nationally representative data in the United States needs 
further examination. This study examined the impacts of patient demographics and 
medication choices on patient’s health status and associated medication costs in the 
United States. METHODS: A retrospective cross-sectional study was conducted using 
the 2007 Medical Expenditure Panel Survey (MEPS) database. Information on patient 
demographics, health status, medication utilization, and medication costs were 
obtained from the database representing 605,089 patients with psoriasis. Weighted 
multiple linear regressions were used to examine the impacts of patient demographics 
and medication choices on patient’s health status and associated medication costs. 
RESULTS: Weighted multiple linear regression analyses indicated that the use of 
topical corticosteroids yielded 23.0% lower annual medication costs (compared to 
nonusers in logarithm format; P = 0.00), whereas the use of biological/systemic agents 
yielded 41.8% higher annual medication costs (compared to nonusers in logarithm 
format; P = 0.00). The study population using topical corticosteroids had 35.0% 
improvement in SF-12 PCS scores (compared to nonusers; P = 0.00), whereas patients 
using biological/systemic agents had 8.2% improvement in SF-12 PCS scores (com-
pared to nonusers; P = 0.00. ) The use of biological agents was elevated compared to 
previous studies. CONCLUSIONS: We observed an association with medication 
choice for psoriasis treatment on associated patient health status and medication 
spending in the United States. The retrospective nature of the study precludes assess-
ment of causality, but encouraging use of topical treatments may be an effective means 
to reduce psoriasis management costs. 
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OBJECTIVES: The objective of this study is to identify an existing instrument which 
could measure the health related quality of life of myopia patients receiving refractive 
surgery such as LASIK for group-level and individual-level decision-making. 
METHODS: Seven instruments were identiﬁ ed through a comprehensive literature 
search. Based on the criteria deﬁ ned by Scientiﬁ c Advisory committee of the Medical 
Outcome Trust (2002), selected instruments were evaluated using 12 criteria related 
to conceptual model, reliability (internal consistency and test-retest), validity(content 
validity and construct validity), responsiveness(cross-sectional and longitudinal), 
interpretability(availability of norms and quality of norms), burden(respondent and 
administrator), and depth. RESULTS: For the seven identiﬁ ed instruments, two were 
excluded because language criteria and one was excluded because it measured satisfac-
tion, not HRQOL. The remaining four instruments included National Eye Institute 
Refractive Error Quality of Life (NEI-RQL), Refractive Status and Vision Proﬁ le 
(RSVP), Quality of Life Impact of Refractive Correction (QIRC), Quality-of-life Scale 
for Myopia (QOLM). For 12 individual decision-making criteria, NEI-RQL, RSVP, 
QIRC and QOLM met 7, 7, 6, 5 criteria, respectively. For 12 group-level decision-
making criteria, NEI-RQL, RSVP, QIRC and QOLM met 9, 7, 8, 7 criteria, respec-
tively. CONCLUSIONS: Existing instruments do not fully meet the evaluation criteria. 
Most instruments lacked information or had problems with reliability (individual-level 
decision-making), longitudinal responsiveness, administrator burden, and depth. This 
study results showed that NEI-RQL met the most of the criteria. 
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OBJECTIVES: The NEI-RQL-42 developed by RAND Corporation in US English is 
a reliable, valid, and sensitive 42-item measure of the impact of refractive status on 
patients’ day-to-day life. No Simpliﬁ ed Chinese or Hindi versions existed previously. 
For an international study, the NEI-RQL-42 had to be translated and linguistically 
validated in Simpliﬁ ed Chinese for China and Hindi for India. METHODS: A stan-
dardized linguistic validation methodology was conducted by specialists for each 
target country: 1) concept deﬁ nition; 2) dual forward translations by independent 
native-speaking linguists; 3) reconcili-ation of the forward translations; 4) back trans-
lation into English by a native speaking linguist; 5) resolution of the back translation; 
6) international harmonization; 7) clinician (Ophthalmologist) review; 8) cognitive 
debrieﬁ ng comprehension interviews on ﬁ ve Mandarin/Simpliﬁ ed Chinese and ﬁ ve 
Hindi native-speaking patients who are either pre- or post-cataract surgery; and 9) 
ﬁ nal proofreading. RESULTS: The main challenge on the conceptual level was the 
English original made extensive use of driving scenarios during the day and night in 
the US English source instrument to elicit responses. For Hindi and Simpliﬁ ed Chinese, 
driving scenarios were supplemented with walking and cycling, which were more 
relevant in the local context without compromising the conceptual intent of the source 
instrument. On the linguistic level, translating some of the frequency terms required 
discussion with the developer to identify a solution, as the gradation between the 
surrounding English response options was difﬁ cult to exactly match on a conceptual 
level in the target language due to linguistic limitations. CONCLUSIONS: According 
to the rigorous methodology used, with some minor adjustments, the Mandarin and 
Hindi versions of the NEI-RQl-42 were qualitatively conceptually equivalent and 
culturally relevant. The Simpliﬁ ed Chinese and Hindi versions were successfully lin-
guistically validated to measurement of the impact of refractive error on patients’ 
day-to-day lives and facilitate the comparison and pooling of data. 
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OBJECTIVES: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis 
(TEN), caused by allopurinol therapy, are strongly associated with the human leuko-
cyte antigen (HLA), HLA-B*5801. It was unclear at what price the genetic testing 
would be a cost-effective strategy compared to no testing. This study aims to determine 
the range of genotyping cost that would be cost-effective from health-care provider 
perspective. METHODS: A decision analytic model was used to estimate the cost-
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effectiveness of HLA-B*5801 genotyping compared to no testing. The incidence of 
SJS/TEN was estimated based on case reports from Health Product Vigilance Center 
of Thailand in year 2009. The prevalence of HLA-B*5801 was obtained from Thai 
population reported in dbMHC database, while the association of gene and SJS/TEN 
was based on a meta-analysis. Cost of SJS/TEN management and case-fatality rate 
were derived from National Inpatient Governmental Hospital Database in year 2007. 
We used PG5801 DNA detection kit as a genotyping tool with 100% sensitivity and 
speciﬁ city. We varied genotyping costs and selected values that would make the cost-
effectiveness values being 100,000 or 300,000 THB/life-year gained. One-way sensitiv-
ity analysis was undertaken to identify inﬂ uential parameters. RESULTS: The 
estimated life-years (LY) were 21.9999 and 21.9964 for testing and no testing groups, 
respectively. Setting the genotyping cost as 393 and 1085 THB resulted in a potentially 
cost-effectiveness range of 100,000 and 300,000 THB/LY, respectively. The most 
inﬂ uential parameters were the cost of genotyping and SJS/TEN management. 
CONCLUSIONS: Pharmacogenetic testing for HLA-B*5801 appears to be potentially 
cost-effective if the testing cost falls in the range of 393 and 1085 THB. It was impor-
tant to note that this analysis has not taken into account sequelaes associated with 
SJS/TEN and has not performed based on the societal perspective yet. Policymakers 
should consider our ﬁ ndings for guiding health policy during decision-making process. 
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
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OBJECTIVES: A US hospital-based economic model was developed to quantify the 
potential cost savings associated with use of an improved non-immunogenic bypassing 
agent with faster bleeding resolution, sustained control and a reduced need for retreat-
ment in order to estimates the inpatient costs for on-demand treatment of bleeds of 
hemophilia patients with inhibitors. METHODS: An Excel-based model patterned the 
inpatient care associated with use of currently available bypassing agents: plasma-
derived activated prothrombin complex concentrate (pd-aPCC) and recombinant 
Factor VIIa (rFVIIa). We used the model to simulate the potential impact of faster 
bleeding resolution associated with an improved bypass agent by examining a realistic 
range of theoretical improvements to the rFVIIa proﬁ le. The model was parameterized 
with treatment-speciﬁ c average resource use, service and pharmacy costs, and source 
admission estimates based on a retrospective analysis of the Premier Perspective™ 
Database, including 1218 inpatient stays with an ICD-9 diagnosis of hemophilia A 
that were identiﬁ ed from 2003–2008. All costs are reported in 2008 USD. RESULTS: 
In the baseline analysis, the average per-patient costs associated with the inpatient 
treatment of hemophilia with inhibitors were slightly lower with rFVIIa as compared 
with pd-aPCC ($78,086 vs. $78,141). The observed cost difference was attributable 
to an observed difference in the percentage of inpatient stays where the patient was 
admitted through the ER associated (rFVIIa: 54%; pd-aPCC: 80%). Exploratory 
sensitivity analyses showed that a potentially faster-acting non-immunogenic treat-
ment (e.g., 10% reduction in length of stay per patient admittance and a 10% reduc-
tion in average duration of bypass agent therapy per patient admittance) could impart 
appreciable incremental cost savings of $7867 (10.1%) compared with pd-aPCC 
treatment. CONCLUSIONS: Our analysis showed that the availability of more effec-
tive bypassing agents with faster bleed resolution may have the potential to confer 
signiﬁ cant inpatient cost savings through reductions in length of stay and duration of 
bypass agent treatment. 
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OBJECTIVES: To examine utilization of health-care services and factor concentrate 
among persons with hemophilia A receiving care at US Hemophilia Treatment Centers 
(HTCs). METHODS: Hemophilia Utilization Group Study (HUGS-Va) is a prospec-
tive multicenter study evaluating burden of illness and cost of care in persons with 
hemophilia A in the United States. Patients or parents of patients < 18 from six HTCs 
completed a standardized interview, including demographics, health insurance cover-
age, barriers to care and treatment pattern. One-year clinical data and two-year dis-
pensing records were abstracted for health care and factor utilization. Annual factor 
use and costs were calculated as the average of two-year data. Generalized linear 
model with Poisson distribution was used to assess the association between factor 
replacement and emergency room visits after adjusting for covariates. RESULTS: Of 
329 participants (50% adults), 68% had severe hemophilia. Ninety-one percent 
reported using health services at least once during the year: 65% had a HTC compre-
hensive evaluation, 33% visited a clinician, 21% had physical therapy, 28% visited 
the emergency room, and 14% were hospitalized. Emergency room visits per person-
year were 58% lower among prophylaxis users (vs.episodic) after adjusting for age, 
employment, and insurance coverage (RR = 0.42, P = 0.002). Patients without inhibi-
tors and severe disease had signiﬁ cantly more factor dispensed (4236 u/kg/yr), com-
pared to those with moderate (1089 u/kg/yr) or mild (582 u/kg/yr) disease (P < 
0.0001). The average factor cost was $165,188 (median: $104,170) per patient-year 
in persons without inhibitors and $700,272 (median: $197,621) in patients with 
inhibitors. CONCLUSIONS: Patients access an array of comprehensive health services 
provided by HTCs. Prophylactic infusion of factor may be associated with decreased 
health-care utilization compared to episodic treatment. 
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OBJECTIVES: Thalassaemia is one of the major public health problems in Thailand. 
Using appropriate iron chelating agents could prevent thalassemia-related complica-
tions which are costly to the health-care system. This study aims to evaluate the 
cost-effectiveness of Deferoxamine (DFO), Deferiprone (DFP), and Desferasirox 
(DFX) in transfusion-dependent thalassaemia patients from the societal perspective. 
METHODS: A Markov model was used to project the life time costs and outcomes 
represented as quality-adjusted life-years (QALYs). Clinical efﬁ cacy and safety of all 
therapeutic options were obtained from a systematic review and clinical trials. Transi-
tion probabilities were derived from literatures while costs were obtained from Thai 
Drug and Medical Supply Information Center, Diagnostic Related Group (DRG) and 
other Thai literatures. Discounting rate of 3% was used. Incremental cost-effectiveness 
ratios were presented as values of year 2009. A series of sensitivity analysis and cost 
effectiveness analysis curve (CEAC) were performed. RESULTS: Compared with DFO, 
using DFP is dominant with cost-savings of US$ 91,107 without QALYs gained. 
Comparing DFX with DFO, the incremental cost was US$ 129,565 and incremental 
QALY was 5.35 with an incremental cost-effectiveness ratio of US$ 22,463. When 
compared to DFP, an incremental cost-effectiveness ratio of DFX was US$ 38,258 per 
QALY. Cost effectiveness analysis curve (CEAC) showed that the probability of DFX 
being cost-effective was 0% when compared with either DFO or DFP, based on the 
cost-effectiveness cut-off value of US$ 2,902 per QALY. When compared to DFP, 
DFX is cost-effective only if DFX cost was lowered from US$ 14.6 to US$ 4 per tablet. 
CONCLUSIONS: Our ﬁ ndings suggest that using DFP is cost-saving when compared 
with the conventional therapy, while using DFX is not cost-effective compared with 
both DFO and DFP. Policymakers and clinicians may consider using such information 
for aiding policy decision-making process in Thailand. 
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OBJECTIVES: To evaluate the cost-effectiveness of deferasirox (DFS) versus deferox-
amine (DFO) in patients with β-thalassaemia major from a Hong Kong (HK) public 
health-care system perspective. METHODS: A Markov model previously developed 
for the United States was adapted to examine the potential cost-effectiveness with DFS 
versus DFO based on lifetime costs and QALYs gained in transfusion-dependent 
β-thalassaemia patients in HK. Patients were assumed to have initiated chelation 
therapy at 3 years of age and have received prescribed dosages of DFS or DFO that 
have been shown to be similarly effective in β-thalassaemia patients. Probabilities of 
complications of iron-overload and death due to poor compliance with chelation 
therapy were estimated using data from recently published studies. Iron chelator 
dosages, costs of administration, and iron overload-related complications were col-
lected from hospital medical records (from January 2004 to December 2009) of 
transfusion-dependent β-thalassaemia patients. Health-state utility values were based 
on a recent study of patients’ preferences for oral versus infusional therapy and pub-
lished literature. A 5% annual discount rate was used. RESULTS: Compared with 
DFO, DFS yielded an additional 3.15 QALYs gained per patient at an additional 
lifetime expected cost of $156,881 USD ($1.22M HKD) per patient; the cost per 
QALY gained was $US49,761 ($388K HKD). The results were sensitive to the esti-
mated infusional administration costs for DFO, the rates of compliance associated 
with oral versus infusional therapy, estimates of the daily dose of DFS, and unit costs 
of each chelator. CONCLUSIONS: Based on the WHO recommended thresholds that 
any incremental cost-effectivess ratio lower than three-times the GDP per capita can 
be considered as cost-effective (GDP of HK in 2009 was $US 29,902), results of this 
study suggest that DFS is probably a cost-effective iron chelator for patients with 
transfusion-dependent β-thalassaemia. 
